Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Page 1
Nurse Staffing and Veteran Outcomes in the Veterans Health Administration's Community Living Centers.
Brown LM, Gauss CH, Billings P, Minor L, Moore JT, Sawyer LM, Sparks D, Sullivan SC. Brown LM, et al. Among authors: sawyer lm. J Nurs Care Qual. 2023 Oct-Dec 01;38(4):297-303. doi: 10.1097/NCQ.0000000000000700. Epub 2023 Feb 24. J Nurs Care Qual. 2023. PMID: 36827702
BACKGROUND: The demand for nursing care is rising in the long-term care setting. Nurse staffing is a crucial measure linked to health care quality measure outcomes. ...
BACKGROUND: The demand for nursing care is rising in the long-term care setting. Nurse staffing is a crucial measure linked to health …
Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year.
Yasmeen N, Sawyer LM, Malottki K, Levin LÅ, Didriksen Apol E, Jemec GB. Yasmeen N, et al. Among authors: sawyer lm. J Dermatolog Treat. 2022 Feb;33(1):204-218. doi: 10.1080/09546634.2020.1743811. Epub 2020 Apr 2. J Dermatolog Treat. 2022. PMID: 32202445 Free article.
PURPOSE: To compare PASI outcomes of approved biologics and apremilast after 1 year of treatment. METHODS: A systematic review identified RCTs and long-term extensions reporting PASI 75, 90, and 100 responses in adults with moderate-to-severe psoriasis. ...
PURPOSE: To compare PASI outcomes of approved biologics and apremilast after 1 year of treatment. METHODS: A systematic review identified RC …
Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countries.
Balak DMW, Carrascosa JM, Gregoriou S, Calzavara-Pinton P, Bewley A, Antunes J, Nyeland ME, Viola MG, Sawyer LM, Becla L. Balak DMW, et al. Among authors: sawyer lm. J Dermatolog Treat. 2021 Nov;32(7):701-708. doi: 10.1080/09546634.2019.1707754. Epub 2020 Mar 6. J Dermatolog Treat. 2021. PMID: 31940225
PURPOSE: To compare the short-term cost and effectiveness of calcipotriol/betamethasone dipropionate (Cal/BD) cutaneous foam against nonbiologic systemics in psoriasis patients for whom oral systemic or topical therapy is considered appropriate in seven European countries. …
PURPOSE: To compare the short-term cost and effectiveness of calcipotriol/betamethasone dipropionate (Cal/BD) cutaneous foam against …
Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response.
Sawyer LM, Malottki K, Sabry-Grant C, Yasmeen N, Wright E, Sohrt A, Borg E, Warren RB. Sawyer LM, et al. PLoS One. 2019 Aug 14;14(8):e0220868. doi: 10.1371/journal.pone.0220868. eCollection 2019. PLoS One. 2019. PMID: 31412060 Free PMC article.
CONCLUSIONS: In the NMA brodalumab, ixekizumab, risankizumab and guselkumab showed the highest levels of short-term efficacy. There were differences in efficacy between treatments within the same class. Longer-term analyses are needed to understand differences betwe …
CONCLUSIONS: In the NMA brodalumab, ixekizumab, risankizumab and guselkumab showed the highest levels of short-term efficacy. There w …
Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.
Sawyer LM, Cornic L, Levin LÅ, Gibbons C, Møller AH, Jemec GB. Sawyer LM, et al. J Eur Acad Dermatol Venereol. 2019 Feb;33(2):355-366. doi: 10.1111/jdv.15277. Epub 2018 Oct 31. J Eur Acad Dermatol Venereol. 2019. PMID: 30289198 Free PMC article.
BACKGROUND: Patients with moderate-to-severe psoriasis require long-term treatment, yet few trials compare outcomes beyond a short-term induction period. Quantitative comparisons of long-term outcomes in patients with psoriasis are limited. To our knowledge, …
BACKGROUND: Patients with moderate-to-severe psoriasis require long-term treatment, yet few trials compare outcomes beyond a short- …
Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke.
Diamantopoulos A, Sawyer LM, Lip GY, Witte KK, Reynolds MR, Fauchier L, Thijs V, Brown B, Quiroz Angulo ME, Diener HC. Diamantopoulos A, et al. Among authors: sawyer lm. Int J Stroke. 2016 Apr;11(3):302-12. doi: 10.1177/1747493015620803. Epub 2016 Jan 6. Int J Stroke. 2016. PMID: 26763916
We evaluated whether atrial fibrillation detection using continuous long-term monitoring with an insertable cardiac monitor is cost-effective for preventing recurrent stroke in patients with cryptogenic stroke, in comparison to the standard of care. ...
We evaluated whether atrial fibrillation detection using continuous long-term monitoring with an insertable cardiac monitor is cost-e …
Biological therapies for the treatment of severe psoriasis in patients with previous exposure to biological therapy: a cost-effectiveness analysis.
Sawyer LM, Wonderling D, Jackson K, Murphy R, Samarasekera EJ, Smith CH. Sawyer LM, et al. Pharmacoeconomics. 2015 Feb;33(2):163-77. doi: 10.1007/s40273-014-0226-y. Pharmacoeconomics. 2015. PMID: 25526841
A meta-analysis of these data provided probabilities of achieving PASI response (50/75/90) in the short term, and published evidence and assumptions were used to predict outcomes over the longer term. ...Future studies should be designed to evaluate the clinical eff …
A meta-analysis of these data provided probabilities of achieving PASI response (50/75/90) in the short term, and published evidence …